GlassScriptPhysician profile
Sara E Sargent
NPI 1083803779
$1,807.05
in general payments reported to CMS, 2019-2025
26 companies · $598 in 2025
The $598 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.38 · 2022: $403 · 2023: $439 · 2024: $272 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.08 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $197.91 | 2022-2025 | |
| Astellas Pharma US INC | $142.11 | 2024-2025 | Veozah |
| Novo Nordisk INC | $82.06 | 2021-2025 | Wegovy, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $78.69 | 2022 | |
| Exact Sciences Corporation | $77.62 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $77.19 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Pfizer INC. | $76.09 | 2023-2025 | |
| Corcept Therapeutics | $68.04 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $59.12 | 2023-2024 | Trelegy Ellipta |
| Antares Pharma, INC. | $42.18 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.95 | 2022-2023 | Spiriva Respimat |
| Lilly USA, LLC | $35.32 | 2023 | Jardiance, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.62 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $32.00 | 2023-2024 | Breztri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $29.13 | 2022 | |
| Avanir Pharmaceuticals, INC. | $25.91 | 2022 | |
| Sumitomo Pharma America, INC. | $23.18 | 2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.07 | 2022 | |
| Zealand Pharma US, INC. | $19.11 | 2022 | |
| Verona Pharma, INC. | $18.92 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $17.74 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $15.23 | 2023 | Rexulti |
| Shield Therapeutics INC | $14.77 | 2025 | |
| Amgen INC. | $14.69 | 2023 | Otezla, Repatha |
| Impel Pharmaceuticals INC. | $14.32 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Sargent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.